Alzheimer's disease

Carewell Celebrates the Heart of Caregiving with 2024 Caregiver Award Winners

Retrieved on: 
Friday, February 16, 2024

MIAMI, Feb. 16, 2024 /PRNewswire/ -- Carewell, the leading e-commerce resource for caregivers, today announced the winners of its 2024 Carewell Caregiver Awards, celebrating caregivers' compassion, selflessness and devotion. The Caregiver Awards, which recognize the diversity of caregiver relationships beyond traditional ones, are sponsored by Attends, a leader in adult incontinence products.

Key Points: 
  • MIAMI, Feb. 16, 2024 /PRNewswire/ -- Carewell , the leading e-commerce resource for caregivers, today announced the winners of its 2024 Carewell Caregiver Awards, celebrating caregivers' compassion, selflessness and devotion.
  • The Caregiver Awards, which recognize the diversity of caregiver relationships beyond traditional ones, are sponsored by Attends, a leader in adult incontinence products.
  • To recognize the many forms of caregiving, the Caregiver Awards had six varying categories, with $10,000 in total prizes.The categories and winners included:
    Parent Caregiver Award: Stephanie Stanley, for her dedication as the full-time caregiver to her son Peyton, who faces severe health challenges.
  • Companion Caregiver Award: Jason Castro, for his compassion and support for his girlfriend with cerebellar hypoplasia.

UT Health San Antonio doctors among first to implant rechargeable deep brain stimulation device

Retrieved on: 
Thursday, February 15, 2024

SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.

Key Points: 
  • SAN ANTONIO, Feb. 15, 2024 /PRNewswire-PRWeb/ -- Doctors at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) are among the nation's first to implant a newly approved sensing rechargeable deep brain stimulation device with a 15-year battery life allowing more continual treatment of patients with movement disorders.
  • Deep brain stimulation, known as DBS, is the placement of electrodes in the brain connected to a battery-operated generator in the chest similar to a cardiac pacemaker.
  • Note: Neither UT Health San Antonio nor University Health endorses commercial products or services by name.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million.

BIOVIE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 15, 2024

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI) and reminds investors of the March 19, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $25,000 investing in BioVie stock or options between August 5, 2021 and November 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Upon trial completion, the Company found significant deviation from protocol and Good Clinical Practice (GCP) violations at 15 sites.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioVie’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Alarming Study Reveals Safety Limits are Exceeded for Mercury Exposure from Dental Amalgams in Pregnant Women in the U.S.

Retrieved on: 
Wednesday, February 14, 2024

This study presents groundbreaking findings on the mercury vapor exposure from dental amalgams of pregnant women in the United States.

Key Points: 
  • This study presents groundbreaking findings on the mercury vapor exposure from dental amalgams of pregnant women in the United States.
  • In women with amalgam surfaces, the number of surfaces, correlated with significantly higher median daily urinary mercury excretion compared to women without amalgams.
  • Notably, close to 30% of these women received daily mercury vapor doses from amalgams exceeding the safety limits set by the U.S. Environmental Protection Agency.
  • Mercury amalgam dental fillings should be banned by the FDA as they pose a serious risk to the health of all individuals who have amalgam fillings, especially pregnant women and those of reproductive age."

Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.

Key Points: 
  • SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead.
  • "We are delighted to welcome Dr. Johnson-Pratt to Aspen Neuroscience," said Damien McDevitt, PhD, Aspen Neuroscience president and chief executive officer.
  • "As we prepare to enter the clinic with our first-in-human trial for Parkinson's disease, we are deepening our investment in the company's development.
  • Lisa is a board director at Assembly Bio and Tracon Pharma, and is the board chair of Young People in Recovery.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, February 14, 2024

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation

Retrieved on: 
Tuesday, February 13, 2024

LONDON, Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC)  Rebrands as Argent BioPharma in Strategic TransformationMarking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders. This rebranding is the culmination of an extensive restructuring, incorporating significant American capital and operational revisions. Poised for growth, Argent BioPharma is now set to emerge as a key player in the biopharmaceutical industry, leveraging cutting-edge advancements in Polypharmacology and Nanotechnology. With its presence on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is well-positioned to make substantial contributions to enhancing medical treatment accessibility.

Key Points: 
  • LONDON, Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC)  Rebrands as Argent BioPharma in Strategic Transformation
    Marking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders.
  • Poised for growth, Argent BioPharma is now set to emerge as a key player in the biopharmaceutical industry, leveraging cutting-edge advancements in Polypharmacology and Nanotechnology.
  • With its presence on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is well-positioned to make substantial contributions to enhancing medical treatment accessibility.
  • As Argent BioPharma transitions from MGC Pharma, it stands ready to lead a new era in biopharmaceuticals, promising accessible and impactful healthcare solutions on a global scale.

Free immersive online training available for California caregivers

Retrieved on: 
Monday, February 12, 2024

GLENDALE, Calif., Feb. 12, 2024 /PRNewswire/ -- California caregivers can see the world through the eyes of the people they care for through a free immersive online training developed by Embodied Labs, in partnership with Front Porch and the Front Porch Center for Innovation and Wellbeing (FPCIW).

Key Points: 
  • Front Porch Center for Innovation and Wellbeing partners with Embodied Labs to provide direct care workers, friends and family caregivers with cutting edge technology
    The award-winning caregiver training platform is available for paid care workers, as well as for family or friend caregivers of older adults in California.
  • FPCIW is partnering as a Center of Excellence with Embodied Labs, a CalGrows Innovation Fund Award Winner , to offer free training to direct care workers and friends/family caregivers in California.
  • "Through immersive experiences, formal and informal caregivers can embody the perspectives and conditions of other people, gaining a unique understanding not found in traditional training tools."
  • "Embodied Labs is positioned to support these heroes by providing caregiver training and tools that build empathy and understanding," says Park.

BIVI Shareholders Who Lost Money Should Contact Robbins LLP for Information about the BioVie Inc. Class Action

Retrieved on: 
Saturday, February 10, 2024

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against BioVie Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brooge, and Cassava and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 10, 2024

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • For more information on the Brooge class action go to: https://bespc.com/cases/BROG
    Cassava is a clinical-stage biotechnology company.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • For more information on the Cassava class action go to: https://bespc.com/cases/SAVA